N4-Based Multimodality Chelator Linker for Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging-based drug design strategies face challenges such as steric interference, reduced solubility, and altered pharmacokinetics due to the attachment of large molecular weight fluorescent dyes to targeting agents, limiting the clinical translation of difunctional compounds for cancer treatment.
Innovation Solution
Development of N4-based multimodality chelator (MMC) compounds that incorporate a cell targeting group, a radionuclide, a fluorophore, or a therapeutic agent, using linkers like alkanediyl or peptide groups to maintain preferred targeting moiety-chelator orientation and functionalize with therapeutic payloads, enabling multiple imaging modalities and therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If large molecular weight fluorescent dyes are attached to targeting agents to create difunctional compounds for imaging and therapy, then imaging capability is improved, but steric interference and reduced solubility occur
Solution Approach 1:
The patent introduces a novel linker chelator complex as an intermediary component between the targeting agent and fluorescent dye. This linker chelator complex (containing structures like DOTA, NOTA, or N4-based chelators) serves as a mediating structure that provides appropriate spacing and chemical environment to reduce steric interference while maintaining solubility through its polyether or polyamino acid side chains, thus resolving the contradiction between imaging capability and harmful side effects
Solution Approach 2:
The patent creates composite structures by combining multiple functional components: targeting agent + linker chelator complex + fluorescent dye + radionuclide. This composite approach allows each component to contribute its specific function while the overall structure maintains stability and solubility, overcoming the limitations of simple dye-antibody conjugates
2Difficulty of detecting and measuring
If fluorescent dyes are conjugated to targeting agents to enable imaging, then imaging function is enhanced, but pharmacokinetics are altered and clinical translation is limited
Solution Approach 1:
The patent designs a universal linker chelator complex platform that can simultaneously support multiple imaging modalities (fluorescence, PET, SPECT, MRI) and therapeutic payloads (radionuclides, chemotherapeutics). This multi-functional design ensures consistent pharmacokinetics across different conjugate types while enabling comprehensive imaging and therapy capabilities, thus improving reliability for clinical translation
Solution Approach 2:
The patent modifies key parameters of the conjugate structure including the linker length, chelator type, and side chain composition to optimize pharmacokinetic properties. By adjusting these parameters, the patent maintains stable blood circulation, appropriate tissue distribution, and reduced immunogenicity, thereby enabling clinical translation while preserving imaging function
3Ease of manufacture
If commercially available chelators are used to attach radionuclides to targeting agents, then radiolabeling is achieved, but preferred targeting moiety-chelator orientation and therapeutic payload functionalization cannot be maintained
Solution Approach 1:
The patent segments the conjugate into distinct functional modules: targeting agent, linker, chelator complex, and payload. This segmentation allows independent optimization of each component while maintaining proper orientation through the designed linker-chelator architecture. The modular design enables versatile functionalization with different therapeutic payloads without compromising radiolabeling efficiency or targeting orientation
Solution Approach 2:
The linker chelator complex serves as an intermediary structure that maintains proper spatial orientation between the targeting moiety and the radionuclide. This intermediary component provides a stable attachment point for radionuclides while preserving the targeting agent's binding affinity and orientation, simultaneously enabling further functionalization with therapeutic payloads through available functional groups on the linker or chelator
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MMC compounds facilitate enhanced imaging and therapeutic efficacy by maintaining targeting specificity and radiolabeling efficiency, allowing for effective visualization and treatment of cancers through PET, SPECT, MRI, and optical imaging techniques.
Implementation Method 1
N4-based multimodality chelator (MMC) group, a cell targeting group, a radionuclide
Implementation Method 2
fluorophore group... effective visualization and treatment of cancers through PET, SPECT, MRI, and optical imaging techniques
Data Source
AI summary
In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula:wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.